lu ag06479

Lu AG06479 is an investigational small molecule drug that was originally developed by Abide Therapeutics and later acquired by H. Lundbeck A/S. It acts as a selective inhibitor of monoacylglycerol lipase (MAGL), an enzyme involved in the degradation of endocannabinoids such as 2-arachidonoylglycerol (2-AG). By inhibiting MAGL, Lu AG06479 is thought to modulate endocannabinoid signaling in the central nervous system, which may have therapeutic potential for various nervous system disorders. The compound entered phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers but development was discontinued before advancing beyond early clinical studies[1][4][10].